External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [ 177 Lu]Lu-PSMA-617 therapy.
文献摘要
Purpose [ 177 Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)-comprising ECOG performance status >0, hemoglobin Methods We retrospectively evaluated 243 mCRPC patients treated with [ 177 Lu]Lu-PSMA-617 at an independent tertiary center. The BRS was calculated at baseline (range 0-3). Endpoints included OS analyzed via Kaplan-Meier estimators, multivariable Cox regression, Harrell's C-index, and time-dependent area under the curve (tAUC). Results The cohort was distributed into BRS 0 (17.6%), BRS 1 (52.7%), BRS 2 (26.1%), and BRS 3 (2.9%). Kaplan-Meier analysis revealed significant risk stratification, with an estimated median OS of 24.0, 15.8, 11.2, and 8.7 months for BRS 0, 1, 2, and 3, respectively (p Conclusion The BRS is a pragmatic, robust, and easily calculable prognostic tool for mCRPC patients undergoing [ 177 Lu]Lu-PSMA-617 therapy, successfully validated in an independent external cohort.